Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).

Autor: Pillai RN; Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, Georgia., Ramalingam SS; Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, Georgia., Thayu M; Janssen Research & Development, LLC, Titusville, New Jersey., Lorenzini P; Janssen Research & Development, LLC, Spring House, Pennsylvania., Alvarez Arias DA; Janssen Research & Development, LLC, Spring House, Pennsylvania., Moy C; Janssen Research & Development, LLC, Spring House, Pennsylvania., Hutnick N; Janssen Research & Development, LLC, Spring House, Pennsylvania., Knoblauch R; Janssen Research & Development, LLC, Raritan, New Jersey., Feng H; Janssen Research & Development, LLC, Raritan, New Jersey., Kane C; Janssen Research & Development, LLC, Spring House, Pennsylvania., Horn L; Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Reck M; Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany., Ponce S; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2020 Oct 07; Vol. 2 (2), pp. 100104. Date of Electronic Publication: 2020 Oct 07 (Print Publication: 2021).

Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies.

Autor: Xiang, Minghua^1,2 (AUTHOR), Li, Huayi^1,2 (AUTHOR), Zhan, Yuanyuan³ (AUTHOR), Ma, Ding^1,2 (AUTHOR), Gao, Qinglei^1,2 (AUTHOR) qingleigao@hotmail.com, Fang, Yong^1,2 (AUTHOR) tongjify@163.com

Publikováno v: Molecular Cancer. 4/5/2024, Vol. 23 Issue 1, p1-28. 28p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The ap-2 clathrin adaptor mediates endocytosis of an inhibitory killer cell Ig-like receptor in human NK cells.

Autor: Purdy AK; Immune Cell Development and Host Defense Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111;, Alvarez Arias DA; Immune Cell Development and Host Defense Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111;, Oshinsky J; Immune Cell Development and Host Defense Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111;, James AM; Immune Cell Development and Host Defense Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111;, Serebriiskii I; Developmental Therapeutics Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111; and Kazan Federal University, Kazan 420008, Russia., Campbell KS; Immune Cell Development and Host Defense Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111; kerry.campbell@fccc.edu.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2014 Nov 01; Vol. 193 (9), pp. 4675-83. Date of Electronic Publication: 2014 Sep 19.

In vivo discovery of immunotherapy targets in the tumour microenvironment.

Autor: Zhou P; 1] Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA [2]., Shaffer DR; 1] Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA [2] [3] Jounce Therapeutics, Cambridge, Massachusetts 02138, USA., Alvarez Arias DA; Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Nakazaki Y; Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Pos W; Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Torres AJ; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA., Cremasco V; Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Dougan SK; Whitehead Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA., Cowley GS; Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA., Elpek K; 1] Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA [2] Jounce Therapeutics, Cambridge, Massachusetts 02138, USA., Brogdon J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA., Lamb J; Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA., Turley SJ; Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Ploegh HL; Whitehead Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA., Root DE; Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA., Love JC; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA., Dranoff G; Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Hacohen N; Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA., Cantor H; Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Wucherpfennig KW; Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

Publikováno v: Nature [Nature] 2014 Feb 06; Vol. 506 (7486), pp. 52-7. Date of Electronic Publication: 2014 Jan 29.